GlassScriptPhysician profile
Faiz Afridi
NPI 1124480132
$3,552.49
in general payments reported to CMS, 2019-2025
24 companies · $877 in 2025
The $877 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $733 · 2024: $1,943 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,494 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $18.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,493.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $18.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.02 | 2023-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $522.85 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Qol Medical, LLC | $205.08 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $200.76 | 2023-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $193.29 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $191.52 | 2023-2024 | Entyvio, Eohilia, Gattex |
| Braintree Laboratories, INC. | $186.65 | 2023-2025 | Suflave, Sutab |
| Lilly USA, LLC | $184.02 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $154.24 | 2023-2025 | Stelara, Simponi Aria, Remicade |
| Ardelyx, INC. | $146.35 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $124.16 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $90.82 | 2023-2024 | Dificid |
| Celgene Corporation | $87.93 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $79.63 | 2023-2024 | |
| Celltrion USA INC. | $73.25 | 2024-2025 | Vegzelma, Zymfentra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $65.56 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $64.37 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $58.01 | 2023-2024 | Ocaliva |
| Gilead Sciences, INC. | $52.05 | 2023-2024 | |
| Pfizer INC. | $35.50 | 2023-2024 | |
| Capsovision, INC. | $31.59 | 2023 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $27.24 | 2024 | Iqirvo |
| Pharmacosmos Therapeutics INC. | $21.65 | 2024 | Monoferric |
| Novo Nordisk INC | $19.95 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiz Afridi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.